TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Tizona Therapeutics Stock

Tizona Therapeutics Stock

tizonatx.comHealthcareFounded: 2015Funding to Date: $95.24MM

Tizona Therapeutics is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.

Buy or sell Tizona Therapeutics stockLearn more about Tizona Therapeutics IPO
Register for Details

For more details on financing and valuation for Tizona Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Tizona Therapeutics.

Register Today

Team

Management Team

Scott Clarke
Chief Executive Officer & Board Member
Mark Smyth Ph.D
Advisor Board Member & Scientific Co-Founder
Christine O'Brien
Chief Operating Officer
Shelly Pinto
Controller & Vice President, Finance
Joyson Karakunnel MD
Chief Medical Officer & Senior Vice President
Courtney Beers Ph.D
Chief Scientific Officer
John Corbin Ph.D
Chief Technology Officer

Board Members

Daniel Spiegelman
Scott Clarke
Daniel Hicklin Ph.D
MPM Capital
Nina Kjellson
Canaan Partners
Shelley Chu Ph.D
Abingworth Management
Luke Evnin Ph.D
MPM Capital
Pablo Cagnoni MD
MPM Capital

Other companies like Tizona Therapeutics in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Cytonics
Sector
Healthcare
 
 
Precision Neuroscience
Sector
Healthcare
 
 

News

Xconomy 01/03/2019
Xconomy: Tizona Lands $105M from AbbVie in Cancer Drug R&D Alliance
A cancer immunotherapy teed up for clinical trials by Tizona Therapeutics is now the centerpiece of a new partnership with AbbVie, which is paying the
PE Hub 03/08/2016
Abingworth, Canaan lead $43 mln Series B for Tizona Therapeutics | PE Hub
Tizona Therapeutics Inc, a company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, raised $43 million in Series B funding. Abingworth and Canaan Partners led the round with participation from Lightstone Ventures and existing Series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners.

Trending Companies

Frequently Asked Questions